<DOC>
	<DOC>NCT00481247</DOC>
	<brief_summary>The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Key Male or female, aged 18 years and older Chronic phase, Philadelphia Chromosomepositive chronic myeloid leukemia (CML) Eastern Cooperative Oncology Group Performance Status score of 02 Key Pleural Effusion Uncontrolled cardiovascular disease Significant bleeding disorder unrelated to CML Prior treatment with interferon/imatinib/dasatinib/antiCML systemic treatments except anagrelide/hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia</keyword>
</DOC>